Guggenheim Reaffirms “Buy” Rating for Century Therapeutics (NASDAQ:IPSC)

Century Therapeutics (NASDAQ:IPSC)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a research note issued on Wednesday,Benzinga reports.

IPSC has been the topic of several other research reports. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Century Therapeutics in a research note on Wednesday. Chardan Capital decreased their target price on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Finally, Piper Sandler decreased their target price on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research note on Monday, December 30th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $10.00.

Century Therapeutics Stock Up 2.1 %

Shares of Century Therapeutics stock opened at $0.91 on Wednesday. Century Therapeutics has a 52 week low of $0.86 and a 52 week high of $5.51. The business’s fifty day simple moving average is $1.18 and its 200-day simple moving average is $1.56. The firm has a market cap of $77.38 million, a PE ratio of -0.49 and a beta of 1.76.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The business had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.47 million. During the same quarter in the prior year, the company posted ($0.55) EPS. As a group, equities analysts expect that Century Therapeutics will post -1.63 earnings per share for the current year.

Institutional Investors Weigh In On Century Therapeutics

Several large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its holdings in Century Therapeutics by 257.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company’s stock worth $123,000 after purchasing an additional 51,664 shares during the period. Barclays PLC increased its holdings in Century Therapeutics by 283.6% during the 3rd quarter. Barclays PLC now owns 61,945 shares of the company’s stock worth $106,000 after purchasing an additional 45,797 shares during the period. Geode Capital Management LLC increased its holdings in Century Therapeutics by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock worth $1,656,000 after purchasing an additional 32,614 shares during the period. Wellington Management Group LLP purchased a new stake in Century Therapeutics during the 3rd quarter worth about $284,000. Finally, State Street Corp increased its holdings in Century Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 836,914 shares of the company’s stock worth $1,431,000 after purchasing an additional 57,323 shares during the period. Hedge funds and other institutional investors own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.